About Products Technology Investors News Contact Us Manufacturing KindredBio’s manufacturing facilities provide a seamless transfer from the research and development stage, to the commercial manufacturing stage. Our team maintains control over all steps and processes and provides a unique setting for the development and manufacturing of high-quality, species-specific veterinary biologics. High standards create dependability when your pet needs it most The quality of our biologics and pharmaceuticals is just as important as their development. KindredBio will manufacture products under the appropriate regulatory frameworks such as Title 9 and Title 21 of the Code of Federal Regulations for products being licensed through the USDA and FDA respectively. KindredBio manufacturing sites in Burlingame, CA and Elwood, KS follow Current Good Manufacturing Practices (cGMP). KindredBio acquired, retrofitted, and commissioned an additional manufacturing facility in Elwood, Kansas. We are uniquely positioned to meet the manufacturing needs of our promising pipeline with combined facilities reaching 180,000 square feet of full-spectrum production, from infancy to commercialization, including labeling and packaging end-to-end processes. KindredBio Clinical and Commercial Manufacturing can support the production of a broad range of biologics and pharmaceuticals. This is done through the use of single-use bioreactor (SUB) up to 2,000L in size and the use of automated vial filling, labeling, and cartoning equipment providing flexibility throughout the process. In addition to the Kansas facility, KindredBio commissioned its own dedicated cGMP biologics manufacturing facility in close proximity to our development labs in Burlingame, California. The facility utilizes state-of-the-art single-use technology and has the capacity to meet the requirements for the small scale clinical and commercial KindredBio biologics supply. KindredBio is one of the few biopharmaceutical manufacturers that can capitalize on its production capacity and maintain a steady revenue stream while ensuring all fulfillment needs are met. KindredBio provides full service contract development and manufacturing activities, which are managed by a wholly owned subsidiary, Centaur Biopharmaceutical Services. US-CORP-2000011 FEB-20 NEWS Elanco Announces Agreement to Acquire Kindred Biosciences June 16, 2021 - 6:57 am Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus June 2, 2021 - 8:45 am Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI May 25, 2021 - 8:57 am EVENTS Event: Kindred Biosciences to Present at the LD Micro Invitational XI May 25, 2021 - 9:14 am Event: Kindred Biosciences to Present at the Stifel 2021 Virtual Jaws & Paws Conference May 25, 2021 - 9:12 am Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial Results March 8, 2021 - 8:48 am Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements © Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010